It is likely that its increased specificity for the PI3Kδ isoform, together with reduced hyperglycaemia has enabled the administration of relatively higher doses of idelalisib, leading to enhanced target and pathway suppression, potentially greater than that obtainable with dual PI3K/mTOR inhibitors and pan-Class I PI3K inhibitors. The gene discussed is PIK3CA; the disease is Hyperglycemia.